Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. | Cancers (Basel) | 2022 | 36497493 | PubTator, text mining | PubMed |
| MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. | Pathol Oncol Res | 2022 | 36483096 | PubTator, text mining | PubMed |
| Doublecortin and JIP3 are neural-specific counteracting regulators of dynein-mediated retrograde trafficking. | Elife | 2022 | 36476638 | PubTator, text mining | PubMed |
| Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report. | World J Surg Oncol | 2022 | 36471407 | PubTator, text mining | PubMed |
| RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report. | Front Oncol | 2022 | 36452495 | PubTator, text mining | PubMed |
| Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy. | Front Oncol | 2022 | 36452487 | PubTator, text mining | PubMed |
| Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report. | Medicine (Baltimore) | 2022 | 36451418 | PubTator, text mining | PubMed |
| Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. | Front Oncol | 2022 | 36439495 | PubTator, text mining | PubMed |
| CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements. | Cells | 2022 | 36429042 | PubTator, text mining | PubMed |
| Tough Way In, Tough Way Out: The Complex Interplay of Host and Viral Factors in Nucleocytoplasmic Trafficking during HIV-1 Infection. | Viruses | 2022 | 36423112 | PubTator, text mining | PubMed |
| Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. | Front Oncol | 2022 | 36419902 | PubTator, text mining | PubMed |
| The recycling of AMPA receptors/GABAa receptors is related to neuronal excitation/inhibition imbalance and may be regulated by KIF5A. | Ann Transl Med | 2022 | 36388788 | PubTator, text mining | PubMed |
| Reduction of kinesin I heavy chain decreases tau hyperphosphorylation, aggregation, and memory impairment in Alzheimer's disease and tauopathy models. | Front Mol Biosci | 2022 | 36387285 | PubTator, text mining | PubMed |
| Mechanochemical tuning of a kinesin motor essential for malaria parasite transmission. | Nat Commun | 2022 | 36384964 | PubTator, text mining | PubMed |
| Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). | Lung Cancer | 2022 | 36379124 | PubTator, text mining | PubMed |
| Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. | Nat Commun | 2022 | 36376293 | PubTator, text mining | PubMed |
| Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling. | NPJ Precis Oncol | 2022 | 36369474 | PubTator, text mining | PubMed |
| Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma. | Int J Mol Sci | 2022 | 36362420 | PubTator, text mining | PubMed |
| RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy. | Cancers (Basel) | 2022 | 36358717 | PubTator, text mining | PubMed |
| Rosai-Dorfman Disease between Proliferation and Neoplasia. | Cancers (Basel) | 2022 | 36358690 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=22